Viral Vector Manufacturing Market Size Worth $3.70 Billion By 2028 | CAGR: 18.6%

The global viral vector manufacturing market size is expected to reach USD 3.70 billion by 2028 according to a new study by Polaris Marker Research. The report “Viral Vector Manufacturing Market Share, Size, Trends, Industry Analysis Report, By Vector Type; By Workflow; By Application; By End-Use; By Region; Segment Forecast, 2021 - 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increasing interest in the R&D in novel cell and gene therapies, along with the need for efficient platforms for drug discovery and vaccine discovery, is expected to fuel the market's growth during the forecast period. The growing importance of stem cell technology and the emergence of the COVID-19 pandemic will provide an opportunity for the production market to grow in the coming years.

Gene therapy and cell therapy investigation have been increasing in recent times, and globally over 800 gene therapies are presently being developed at various stages of R&D. The strands are crucial in cancer treatments, such as in the development of CAR-T cells.

For instance, Novartis has developed Kymriah using a lentiviral that has recently received Singapore's first commercial approval from Health Sciences Authority in March 2021. There are more than 200 CAR-T cell therapies that are under various stages of R&D across the globe. All these will augment the growth of the global market.

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/viral-vector-manufacturing-market/request-for-sample

Numerous developments have taken place in the market in recent times, including the introduction of a new platform and collaborations and acquisitions. For instance, in October 2020, Millipore Sigma launched a Virus Express lentiviral production platform that is expected to address the challenges of the production and reduce process development time for investigators. In April 2021, GenScript launched its Research Packaging Service for gene editing cell line development and drug discovery to help in the consistent production of intact and functional viruses.

In April 2021, Albumedix Ltd. entered a collaboration with Cobra Biologics. The partnership is expected to improve process optimization and stability in scale-up manufacturing of adeno-associated strands and lentiviral strands via proprietary recombinant human albumin-based product developed by Albumedix.

In October 2020, Dyno Therapeutics entered into a collaboration and license agreement with Roche, under which CapsidMap platform developed by Dyno will be utilized to generate next-generation adeno-associated virus (AAV) strands to develop novel gene therapies for CNS and liver disorders.

Market participants such as Addgene, Inc., Advanced BioScience Laboratories, Inc. (ABL, Inc.), Aldevron, L.L.C., Audentes Therapeutics, Batavia Biosciences B.V., BioMarin Pharmaceutical, BioNTech IMFS GmbH, Biovion oy, BlueBird Bio, Catalent Inc., Cell and Gene Therapy Catapult, CEVEC Pharmaceuticals GmbH, Cobra Biologics Ltd., Creative Biogene, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., General Electric Company (GE Healthcare), Genezen, Lonza, Merck KGaA, Miltenyi Biotec GmbH, Novasep Holding S.A.S, Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.), RegenxBio, Inc., SIRION Biotech GmbH, Takara Bio.,Thermo Fisher Scientific, VGXI, Inc., Vibalogics GmbH, Vigene Biosciences, Inc., Virovek Incorporation, VIVEbiotech S.L., Waisman Biomanufacturing, Wuxi AppTec Co., Ltd., YPOSKESI are some of the key players operating in the global market.

Polaris Market Research has segmented the Viral Vector Manufacturing market report on the basis of vector, workflow, application, end-use, and region:

Viral Vector Manufacturing, Vector Outlook (Revenue - USD Million, 2016 – 2028)

• Adenovirus
• Retrovirus
• Adeno-Associated Virus (AAV)
• Lentivirus
• Others

Viral Vector Manufacturing, Workflow Outlook (Revenue - USD Million, 2016 – 2028)

• Upstream Processing
  • Vector Amplification and Expansion
  • Vector Recovery/Harvesting
• Downstream Processing
  • Purification
  • Fill Finish

Viral Vector Manufacturing, Application Outlook (Revenue - USD Million, 2016 – 2028)

• Gene and Cell Therapy Development
• Vaccine Development
• Biopharmaceutical and Pharmaceutical Discovery
• Biomedical Research

Viral Vector Manufacturing, End-Use Outlook (Revenue - USD Million, 2016 – 2028)

• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes

Viral Vector Manufacturing, Regional Outlook (Revenue - USD Million, 2016 – 2028)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Austria
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Indonesia
  • Malaysia
  • South Korea
• Latin America
  • Brazil
  • Argentina
  • Mexico
• Middle East & Africa
  • Israel
  • Saudi Arabia
  • South Africa
  • UAE